These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 14509219

  • 1. [Additive antiproteinuric effect of angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor in patients with chronic glomerulonephritis].
    Iimura O, Kusano E, Tanba K, Yanagiba S, Amemiya M, Ando Y, Honma S, Muto S, Asano Y.
    Nihon Jinzo Gakkai Shi; 2003 Jul; 45(5):439-44. PubMed ID: 14509219
    [Abstract] [Full Text] [Related]

  • 2. Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy.
    Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Sekizuka K, Ebihara I, Koide H.
    Am J Nephrol; 2000 Jul; 20(5):373-9. PubMed ID: 11092994
    [Abstract] [Full Text] [Related]

  • 3. Antiproteinuric effect of candesartan cilexetil in patients with chronic glomerulonephritis.
    Kurokawa K, Abe K, Saruta T, Arakawa M, Kikkawa R, Ueda N, Onoyama K, Tomita K, Ogawa N.
    J Renin Angiotensin Aldosterone Syst; 2002 Sep; 3(3):167-75. PubMed ID: 12563567
    [Abstract] [Full Text] [Related]

  • 4. Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease.
    Homma K, Hayashi K, Kanda T, Yoshioka K, Takamatsu I, Tatematsu S, Kumagai H, Wakino S, Saruta T.
    J Hum Hypertens; 2004 Dec; 18(12):879-84. PubMed ID: 15295613
    [Abstract] [Full Text] [Related]

  • 5. Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade.
    Ferrari P, Marti HP, Pfister M, Frey FJ.
    J Hypertens; 2002 Jan; 20(1):125-30. PubMed ID: 11791035
    [Abstract] [Full Text] [Related]

  • 6. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.
    Kanno Y, Takenaka T, Nakamura T, Suzuki H.
    Clin J Am Soc Nephrol; 2006 Jul; 1(4):730-7. PubMed ID: 17699280
    [Abstract] [Full Text] [Related]

  • 7. Dual blockade of the rennin-angiotensin system versus maximal recommended dose of angiotensin II receptor blockade in chronic glomerulonephritis.
    Mori-Takeyama U, Minatoguchi S, Murata I, Fujiwara H, Ozaki Y, Ohno M, Oda H, Ohashi H.
    Clin Exp Nephrol; 2008 Feb; 12(1):33-40. PubMed ID: 18175062
    [Abstract] [Full Text] [Related]

  • 8. Additive antiproteinuric effect of combination therapy with ACE inhibitor and angiotensin II receptor antagonist: differential short-term response between IgA nephropathy and diabetic nephropathy.
    Kim MJ, Song JH, Suh JH, Lee SW, Kim GA.
    Yonsei Med J; 2003 Jun 30; 44(3):463-72. PubMed ID: 12833584
    [Abstract] [Full Text] [Related]

  • 9. Dual blockade of the renin-angiotensin system compared with a 50% increase in the dose of angiotensin-converting enzyme inhibitor: effects on proteinuria and blood pressure.
    Kincaid-Smith P, Fairley KF, Packham D.
    Nephrol Dial Transplant; 2004 Sep 30; 19(9):2272-4. PubMed ID: 15252156
    [Abstract] [Full Text] [Related]

  • 10. [Comparison of ARB and ACEI for renoprotection in chronic glomerulonephritis].
    Kumagai H, Sakata K, Matsuura T, Imai M, Onami T, Iigaya K, Saruta T.
    Nihon Rinsho; 2002 Oct 30; 60(10):2005-13. PubMed ID: 12397699
    [Abstract] [Full Text] [Related]

  • 11. Use of candesartan cilexetil decreases proteinuria in renal transplant patients with chronic allograft dysfunction.
    Omoto K, Tanabe K, Tokumoto T, Shimmura H, Ishida H, Toma H.
    Transplantation; 2003 Oct 27; 76(8):1170-4. PubMed ID: 14578748
    [Abstract] [Full Text] [Related]

  • 12. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy.
    Russo D, Minutolo R, Pisani A, Esposito R, Signoriello G, Andreucci M, Balletta MM.
    Am J Kidney Dis; 2001 Jul 27; 38(1):18-25. PubMed ID: 11431176
    [Abstract] [Full Text] [Related]

  • 13. Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy.
    Sato A, Tabata M, Hayashi K, Saruta T.
    Clin Exp Nephrol; 2003 Sep 27; 7(3):215-20. PubMed ID: 14586718
    [Abstract] [Full Text] [Related]

  • 14. Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
    Esnault VL, Ekhlas A, Nguyen JM, Moranne O.
    Nephrol Dial Transplant; 2010 Jul 27; 25(7):2218-24. PubMed ID: 20106824
    [Abstract] [Full Text] [Related]

  • 15. [Change from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment)].
    Baumgart P, Reismann J, Pohlmeyer H, Düsing R.
    Dtsch Med Wochenschr; 2001 May 11; 126(19):547-50. PubMed ID: 11402910
    [Abstract] [Full Text] [Related]

  • 16. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression.
    Catapano F, Chiodini P, De Nicola L, Minutolo R, Zamboli P, Gallo C, Conte G.
    Am J Kidney Dis; 2008 Sep 11; 52(3):475-85. PubMed ID: 18468748
    [Abstract] [Full Text] [Related]

  • 17. Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease.
    Matsuda H, Hayashi K, Saruta T.
    J Hum Hypertens; 2003 Apr 11; 17(4):271-6. PubMed ID: 12692572
    [Abstract] [Full Text] [Related]

  • 18. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.
    Song JH, Lee SW, Suh JH, Kim ES, Hong SB, Kim KA, Kim MJ.
    Clin Nephrol; 2003 Nov 11; 60(5):318-26. PubMed ID: 14640237
    [Abstract] [Full Text] [Related]

  • 19. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, Tsubakihara Y, Imai E, Shoji T.
    Hypertens Res; 2008 Jan 11; 31(1):59-67. PubMed ID: 18360019
    [Abstract] [Full Text] [Related]

  • 20. Functional and partial morphological regression of established renal injury in the obese zucker rat by blockade of the renin-angiotensin system.
    Sebeková K, Lill M, Boor P, Heidland A, Amann K.
    Am J Nephrol; 2009 Jan 11; 29(3):164-70. PubMed ID: 18753741
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.